New Approaches to the Treatment of Heart Failure

  • Michael M. Givertz
  • Wilson S. Colucci


The major goals in the therapy for chronic heart failure include the amelioration of symptoms and the reduction of morbidity and mortality. There is overwhelming evidence that angiotensin-converting enzyme (ACE) inhibitors and β-blockers achieve both of these goals and therefore are first-line therapy. For patients who remain symptomatic, the clinical utility of digitalis and spironolactone has also been established. Despite the appropriate use of standard therapy, many patients will experience progressive symptoms and reduced survival. Fortunately, an unprecedented number of promising new therapeutic approaches to heart failure have been developed over the past few years.


Heart Failure Obstructive Sleep Apnea Continuous Positive Airway Pressure Chronic Heart Failure Cardiac Resynchronization Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tsutamoto T, Wada A, Maeda Y, et al.: Relation between endothelin1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994, 23:1427–1433.PubMedCrossRefGoogle Scholar
  2. 2.
    Sakai S, Miyauchi T, Kobayashi M, et al.: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996, 384:353–355.PubMedCrossRefGoogle Scholar
  3. 3.
    Hulsmann M, Stanek B, Frey B, et al.: Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998, 32:1695–1700.PubMedCrossRefGoogle Scholar
  4. 4.
    Torre-Amione G, Young JB, Colucci WS, et al.: Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003, 42:140–147.PubMedCrossRefGoogle Scholar
  5. 5.
    Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 1999, 341: 577–585.PubMedCrossRefGoogle Scholar
  6. 6.
    Benedict CR, Francis GS, Shelton B, et al.: Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction: SOLVD Investigators. Am J Cardiol 1995, 75:1151–1157.PubMedCrossRefGoogle Scholar
  7. 7.
    Preibisz JJ, Sealey JE, Laragh JH, et al.: Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983, 5:I129–I138.PubMedGoogle Scholar
  8. 8.
    Lee CR, Watkins ML, Patterson JH, et al.: Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003, 146:9–18.PubMedCrossRefGoogle Scholar
  9. 9.
    Udelson JE, Smith WB, Hendrix GH, et al.: Acute hemodynamic effects of conivaptan, a dual ViA and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001, 104:2417–2423.PubMedCrossRefGoogle Scholar
  10. 10.
    Gheorghiade M, Niazi I, Ouyang J, et al.: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003, 107:2690–2696.PubMedCrossRefGoogle Scholar
  11. 11.
    Gheorghiade M, Galtis WA, O’Connor CM, et al.: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291: 1963–1971.PubMedCrossRefGoogle Scholar
  12. 12.
    Haikala H, Levijoki J, Linden IB: Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol 1995, 27: 2155–2165.PubMedCrossRefGoogle Scholar
  13. 13.
    Slawsky MT, Colucci WS, Gottlieb SS, et al.: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000, 102:2222–2227.PubMedCrossRefGoogle Scholar
  14. 14.
    Kivikko M, Lehtonen L, Colucci WS: Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003, 107: 81–86.PubMedCrossRefGoogle Scholar
  15. 15.
    Follath F, Cleland JG, Just H, et al.: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002, 360:196–202.PubMedCrossRefGoogle Scholar
  16. 16.
    Uretsky BF, Jessup M, Konstam MA, et al.: Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 1990, 82:774–780.PubMedCrossRefGoogle Scholar
  17. 17.
    Lowes BD, Higginbotham M, Petrovich L, et al.: Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol 2000, 36:501–508.PubMedCrossRefGoogle Scholar
  18. 18.
    Shakar SF, Abraham WT, Gilbert EM, et al.: Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998, 31:1336–1340.PubMedCrossRefGoogle Scholar
  19. 19.
    Kass DA, Chen CH, Curry C, et al.: Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. Circulation 1999, 99:1567–1573.PubMedCrossRefGoogle Scholar
  20. 20.
    Cazeau S, Leclercq C, Lavergne T, et al.: Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001, 344:873–880.PubMedCrossRefGoogle Scholar
  21. 21.
    Abraham WT, Fisher WG, Smith AL, et al.: Cardiac resynchronization in chronic heart failure. N Engl J Med 2002, 346:1845–1853.PubMedCrossRefGoogle Scholar
  22. 22.
    St. John Sutton MG, Plappert T, Abraham WT, et al.: Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003, 107:1985–1990.CrossRefGoogle Scholar
  23. 23.
    Morrow JD, Hill KE, Burk RF, et al.: A series of prostaglandin F2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990, 87:9383–9387.PubMedCrossRefGoogle Scholar
  24. 24.
    Mallat Z, Philip I, Lebret M, et al.: Elevated levels of 8-isoprostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998, 97:1536–1539.PubMedCrossRefGoogle Scholar
  25. 25.
    Anker SD, Doehner W, Rauchhaus M, et al.: Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003, 107:1991–1997.PubMedCrossRefGoogle Scholar
  26. 26.
    Cappola TP, Kass DA, Nelson GS, et al.: Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001,104:2407–2411.PubMedCrossRefGoogle Scholar
  27. 27.
    Farquharson CA, Butler R, Hill A, et al.: Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002, 106:221–226.PubMedCrossRefGoogle Scholar
  28. 28.
    Peterson JT, Hallak H, Johnson L, et al.: Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001, 103:2303–2309.PubMedCrossRefGoogle Scholar
  29. 29.
    Drummond AH, Beckett P, Brown PD, et al.: Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 1999, 878:228–235.PubMedCrossRefGoogle Scholar
  30. 30.
    King MK, Coker ML, Goldberg A, et al.: Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Cire Res 2003, 92:177–185.CrossRefGoogle Scholar
  31. 31.
    Miyamoto MI, del Monte F, Schmidt U, et al.: Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A 2000, 97:793–798.PubMedCrossRefGoogle Scholar
  32. 32.
    Hayashidani S, Tsutsui H, Shiomi T, et al.: Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2003, 108:2134–2140.PubMedCrossRefGoogle Scholar
  33. 33.
    Jain M, Der Simonian H, Brenner DA, et al.: Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001, 103:1920–1927.PubMedCrossRefGoogle Scholar
  34. 34.
    Menasche P, Hagege AA, Vilquin JT, et al.: Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Ain Coll Cardiol 2003, 41:1078–1083.CrossRefGoogle Scholar
  35. 35.
    Smits PC, van Geuns RJ, Poldermans D, et al.: Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Ain Coll Cardiol 2003, 42:2063–2069.CrossRefGoogle Scholar
  36. 36.
    Ezekowitz JA, McAlister FA, Armstrong PW: Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003, 107: 223–225.PubMedCrossRefGoogle Scholar
  37. 37.
    Norwich TB, Fonarow GC, Hamilton MA, et al.: Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Ani Coll Cardiol 2002,39:1780–1786.CrossRefGoogle Scholar
  38. 38.
    Mancini DM, Katz SD, Lang CC, et al.: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003, 107:294–299.PubMedCrossRefGoogle Scholar
  39. 39.
    Javaheri S, Parker TJ, Liming JD, et al.: Sleep apnea in 81 ambulatory male patients with stable heart failure: types and their prevalences, consequences, and presentations. Circulation 1998, 97:2154–2159.PubMedCrossRefGoogle Scholar
  40. 40.
    Lanfranchi PA, Somers VK, Braghiroli A, et al.: Central sleep apnea in left ventricular dysfunction: prevalence and implications for arrhythmic risk. Circulation 2003, 107:727–732.PubMedCrossRefGoogle Scholar
  41. 41.
    Kaneko Y, Floras JS, Usui K, et al.: Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 2003, 348:1233–1241.PubMedCrossRefGoogle Scholar
  42. 42.
    Sin DD, Logan AG, Fitzgerald FS, et al.: Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 2000, 102:61–66.PubMedCrossRefGoogle Scholar
  43. 43.
    Moraes DL, Colucci WS, Givertz MM: Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000, 102: 1718–1723.PubMedCrossRefGoogle Scholar
  44. 44.
    Michelakis E, Tymchak W, Lien D, et al.: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002, 105:2398–2403.PubMedCrossRefGoogle Scholar
  45. 45.
    Sastry BK, Narasinhun C, Reddy K, et al.: Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Ann Coll Cardiol 2004, 43:1149–1153.CrossRefGoogle Scholar
  46. 46.
    Bocchi EA, Guimaraes G, Mocelin A, et al.: Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002, 106:1097–1103.PubMedCrossRefGoogle Scholar
  47. 47.
    Katz SD, Parker JD, Bank AJ, et al.:Efficacy and safety of sildenafil citrate in men with erectile dysfunction and congestive heart failure: a randomized placebo-controlled trial. J Card Fail 2003, 9:S57.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2005

Authors and Affiliations

  • Michael M. Givertz
  • Wilson S. Colucci

There are no affiliations available

Personalised recommendations